<p>Bent Jakobsen of Immunocore Ltd. in the United Kingdom, collaborating with Cardiff and Oxford Universities, will test whether a novel biologic therapy, engineered from immune cells, can clear virus from latently-infected HIV cells. If successful, the HIV-infected patients could control the disease without retroviral drugs.</p>


Bent Jakobsen of Immunocore Ltd. in the United Kingdom, collaborating with Cardiff and Oxford Universities, will test whether a novel biologic therapy, engineered from immune cells, can clear virus from latently-infected HIV cells. If successful, the HIV-infected patients could control the disease without retroviral drugs.